诺和锐30对2型糖尿病强化治疗的效果评价  

Clinical investigation of transient intensive insulin aspart 30 treatment type 2 diabetes mellitus

作　　者：赖书华[1] 周善存[2] 王少波[2] 

机构地区：[1]广东医学院附属厚街医院药剂科,东莞523945 [2]广东医学院附属厚街医院内分泌科,东莞523945

出　　处：《中国实用医药》2011年第1期9-10,共2页China Practical Medicine

摘　　要：目的 比较诺和锐30与持续皮下胰岛素输注(CSII)、多次胰岛素皮下注射(MSII)在2型糖尿病强化降糖中的效果。方法将87例2型糖尿病患者随机分成诺和锐30组(n=30)CSII组(n=28)和MSII组(n=29)三组。监测三组2型糖尿病患者治疗前后全天血糖谱的变化,观察并比较血糖达标所需要的时间、胰岛素用量、低血糖发生率等情况。结果诺和锐30组与CSII组和MSII组相比,血糖达标所需的时间、胰岛素用量及低血糖发生率等差异无显著统计学意义(P>0.05)。结论诺和锐30皮下注射与持续皮下胰岛素输注和多次胰岛素皮下注射对2型糖尿病患者强化降糖治疗的效果相当。Objective To compare the curative effect of Novorapid 30,continuous subcutaneous insulin infusion（CSII）and multiple subcutaneous insulin injection（MSII）in type 2 diabetes mellitus（T2DM）.Methods 87 cases with T2DM were randomly divided into 3 groups：Novorapid 30、CSII and MSII.The time of blood glucose for achieving the target,total daily insulin requirement,and frequency of hypoglycaemia,are compared after 90 days.Results There is no significant difference in the time of blood glucose for achieving the target,total daily insulin requirement,and frequency of hypoglycaemia 1 n 3 group（P0.05）.Conclusion The curative effect of Novorapid 30,CSII,MSII are same.

关 键 词：诺和锐30 持续皮下胰岛素输注 多次胰岛素皮下注射 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]